Your browser is no longer supported. Please, upgrade your browser.
Settings
ORMP Oramed Pharmaceuticals Inc. daily Stock Chart
ORMP [NASD]
Oramed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own5.50% Shs Outstand14.57M Perf Week-6.02%
Market Cap81.88M Forward P/E- EPS next Y-1.32 Insider Trans0.01% Shs Float10.48M Perf Month-24.97%
Income-12.50M PEG- EPS next Q-0.31 Inst Own9.50% Short Float1.55% Perf Quarter-23.85%
Sales2.50M P/S32.75 EPS this Y9.30% Inst Trans1.91% Short Ratio4.86 Perf Half Y-32.94%
Book/sh1.15 P/B4.89 EPS next Y-36.10% ROA-32.60% Target Price15.00 Perf Year-34.50%
Cash/sh1.61 P/C3.50 EPS next 5Y- ROE-63.20% 52W Range5.42 - 11.34 Perf YTD-37.56%
Dividend- P/FCF- EPS past 5Y-6.70% ROI-58.20% 52W High-50.44% Beta0.41
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low3.67% ATR0.31
Employees14 Current Ratio4.20 Sales Q/Q0.00% Oper. Margin- RSI (14)27.81 Volatility5.33% 4.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-103.00% Profit Margin- Rel Volume1.14 Prev Close5.49
ShortableYes LT Debt/Eq0.00 EarningsJul 12 Payout- Avg Volume33.42K Price5.62
Recom2.50 SMA20-14.19% SMA50-20.12% SMA200-30.01% Volume38,093 Change2.37%
Dec-11-17Resumed B. Riley FBR, Inc. Buy $20
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Nov-19-15Initiated FBR Capital Outperform $15
Apr-13-15Resumed MLV & Co Buy $27 → $30
Jan-30-14Reiterated Aegis Capital Buy $30 → $35
Jan-08-14Reiterated Aegis Capital Buy $25 → $30
Jan-08-14Initiated MLV & Co Buy $27
Dec-03-13Initiated Aegis Capital Buy $25
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
Jul-12-18 06:36PM  Oramed: Fiscal 3Q Earnings Snapshot Associated Press
Jul-06-18 05:00PM  Oramed Announces Closing of $18.1 Million Registered Direct Offering PR Newswire
Jul-03-18 01:48AM  Oramed Announces $18.1 Million Registered Direct Offering PR Newswire -8.86%
Jun-25-18 08:25AM  Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin PR Newswire
Jun-21-18 08:25AM  Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801 PR Newswire
Jun-19-18 08:25AM  Oramed to be Added to Russell Microcap® Index PR Newswire
Jun-12-18 08:25AM  Oramed to Present at the American Diabetes Association 78th Scientific Sessions PR Newswire
May-30-18 08:25AM  Oramed Patent Allowed in the US for Oral Administration of Proteins PR Newswire +15.61%
May-10-18 09:39AM  For Diabetes Patients, Management Solutions Are As Critical As Medications Market Exclusive
May-07-18 08:25AM  Oramed to Present at Conferences in May PR Newswire
Apr-23-18 08:25AM  Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin PR Newswire
Mar-27-18 08:25AM  Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference PR Newswire
Mar-15-18 08:48AM  Oramed to Present at Oppenheimer's Annual Healthcare Conference PR Newswire
Feb-28-18 08:25AM  Oramed Adds Two New Members to its Scientific Advisory Board PR Newswire
Feb-20-18 08:25AM  Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension PR Newswire
Feb-06-18 08:25AM  Oramed to Present at BIO CEO Investor Conference PR Newswire
Jan-19-18 10:50AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018 Capital Cube
08:25AM  Oramed Pharmaceuticals' CEO Issues Letter to Shareholders PR Newswire
Jan-18-18 07:50AM  Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy ACCESSWIRE
Jan-12-18 12:25PM  Three Diabetes Clinical Trials to Watch in 2018 GuruFocus.com
05:01AM  Oramed reports 1Q loss Associated Press
Nov-14-17 08:00AM  Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule PR Newswire
Oct-31-17 08:35AM  Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins PR Newswire
Oct-24-17 09:25AM  Oramed to Present at the Diabetes Technology Meeting PR Newswire
Oct-17-17 08:40AM  Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists PR Newswire
Sep-25-17 08:55AM  Oramed to Present at the Disruptive Growth Showcase Conference PR Newswire
Sep-22-17 12:55PM  Oramed Now Has a Clear Path to Market With Oral Insulin GuruFocus.com +12.74%
Sep-05-17 09:00AM  Oramed (ORMP): Successful Meeting with FDA for Oral Insulin Zacks Small Cap Research +5.72%
06:00AM  Oramed Announces Successful Meeting with FDA for Oral Insulin PR Newswire
Aug-29-17 08:50AM  Oramed to Present at the Rodman & Renshaw Global Investment Conference PR Newswire
Aug-21-17 04:26PM  3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs GuruFocus.com
Jul-18-17 08:50AM  Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs PR Newswire
Jul-12-17 08:50AM  Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017 PR Newswire
Jul-11-17 08:50AM  Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program PR Newswire
Jul-10-17 10:57AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017 Capital Cube
Jul-06-17 07:16PM  Oramed reports 3Q loss Associated Press
Jul-05-17 08:50AM  Oramed Announces Dual-Listing on Tel Aviv Stock Exchange PR Newswire +8.46%
Jun-27-17 08:45AM  Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule PR Newswire +7.02%
Jun-12-17 08:17AM  Oramed Plans Secondary Listing in Tel Aviv Soon, CEO Kidron Says Bloomberg
Jun-06-17 08:45AM  Oramed to Present at the American Diabetes Association 77th Scientific Sessions PR Newswire
Jun-05-17 10:09AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-18-17 08:45AM  Oramed to Present at Conferences Next Week PR Newswire
May-09-17 08:45AM  Oramed Granted Canadian Patent for GLP-1 Analog Capsule PR Newswire
May-05-17 10:24AM  Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 Capital Cube
May-02-17 01:00PM  Oramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule Zacks Small Cap Research
08:45AM  Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule PR Newswire
May-01-17 01:40PM  Oramed Gaining Strength in Oral Diabetes Market GuruFocus.com
Apr-20-17 08:30AM  Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule PR Newswire
Apr-06-17 05:01AM  Oramed reports 2Q loss Associated Press
Apr-04-17 08:45AM  Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists PR Newswire
Mar-22-17 08:45AM  Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017 PR Newswire
Mar-21-17 09:28AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:45AM  Oramed Appoints Dr. Ronald Law as Chief Strategy Officer PR Newswire
Feb-09-17 05:16PM  While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever GuruFocus.com
Feb-07-17 08:30AM  Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences PR Newswire
Jan-18-17 01:04PM  ORAMED PHARMACEUTICALS INC. Financials
Jan-12-17 05:00AM  Oramed reports 1Q loss
Jan-11-17 05:20PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Dec-30-16 11:15AM  3 Sleeper Biotechs That Could Bounce Back Strong in 2017 24/7 Wall St.
Dec-23-16 12:41PM  Something Strange Is Going On With Oral Insulin GuruFocus.com
Nov-30-16 02:15PM  ORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901 Zacks Small Cap Research
Nov-29-16 08:30AM  Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study PR Newswire
Nov-25-16 11:17AM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
Oct-06-16 08:45AM  Oramed Receives Additional $4 Million Milestone Payment From HTIT PR Newswire
Sep-19-16 09:00AM  Oramed to Present at the Aegis Capital Growth Conference PR Newswire
Sep-09-16 01:50PM  Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree? at Insider Monkey
Sep-07-16 08:00AM  Oramed to Present at the Rodman & Renshaw Global Investment Conference PR Newswire
Sep-06-16 01:38PM  Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasnt at Insider Monkey
Aug-31-16 04:25PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Aug-26-16 08:20AM  Sanofi Just Cant Catch a Break, Knocking at Major Support Again at 24/7 Wall St.
Aug-11-16 11:30AM  Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study
Aug-09-16 12:12PM  The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc. (ORMP) at Insider Monkey
Aug-05-16 12:35PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
05:20AM  Novo's insulin pill shows promise in mid-stage trial
Aug-02-16 09:00AM  Oramed Receives Additional $4 Million Milestone Payment From HTIT PR Newswire
Jul-28-16 04:33PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events
08:15AM  Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo PR Newswire
Jul-27-16 10:15AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jul-26-16 09:00AM  Oramed Appoints Dr. Roy Eldor as Chief Medical Director PR Newswire
Jul-06-16 04:58PM  Oramed reports 3Q loss
03:35PM  ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Jun-22-16 12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
Jun-21-16 09:05AM  Oramed Announces $6.5 Million Milestone Payment from HTIT PR Newswire
Jun-16-16 10:19AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jun-11-16 09:20AM  3 Biotechs That Just Announced Successful Phase 2 Trials at 24/7 Wall St.
Jun-09-16 08:15AM  Oramed to Present at the American Diabetes Association 76th Scientific Sessions PR Newswire
May-23-16 05:14PM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure
May-18-16 03:00PM  ORMP: Oramed Announces Positive Top-Line Data from Phase IIb ORMD-0801 Study
10:56AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
09:23AM  Oramed's Phase IIb Oral Insulin Study Meets Primary Safety And Efficacy Endpoints
07:30AM  Oramed says oral insulin succeeds in midstage type 2 diabetes trial
07:25AM  Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study PR Newswire
May-16-16 09:49AM  Oramed to Present at Oppenheimer Annual Israeli Conference PR Newswire
May-12-16 02:45PM  ORMP: Todays Decline In Share Price Not Justified
May-11-16 08:15AM  Oramed Patent Being Granted in China for Oral Administration of Proteins PR Newswire
May-04-16 08:35AM  ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Apr-28-16 08:15AM  Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar PR Newswire
Apr-12-16 08:15AM  Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent PR Newswire
Apr-07-16 11:30AM  ORMP: Update on Fiscal Second Quarter Financials
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDRON NADAVPresident and CEOJul 11Buy5.92122722958,209Jul 12 05:11 PM
KIDRON NADAVPresident and CEOJul 10Sale5.9861365958,087Jul 12 05:11 PM
Slager David MarkDirectorOct 31Option Exercise3.7716,89263,6091,316,328Nov 01 04:39 PM
Sank LeonardDirectorOct 23Option Exercise6.0012,00472,024294,162Oct 25 04:35 PM
Slager David MarkDirectorAug 17Option Exercise3.77112,613424,0561,299,436Aug 21 01:56 PM
Sank LeonardDirectorAug 15Option Exercise6.0011,26267,572282,158Aug 17 04:22 PM
Li XiaopengDirectorAug 02Buy8.5089,636761,906206,350Aug 03 06:00 PM
Kidron MiriamChief Scientific OfficerAug 02Sale8.5089,636761,90675,000Aug 03 06:00 PM